英国《临床肿瘤杂志》:这类种类的食道癌用易瑞沙实际效果最好

南亚先生 2021年11月11日09:46:48
评论
10

英国《临床肿瘤杂志》:这类种类的食道癌用易瑞沙实际效果最好 。
导 读:紫龙金片和吉非替尼片与此同时吃吗。英国《临床肿瘤杂志》2022年5月24日线上先给http://ascopubs.org/doi/full/10.1200/JCO.2016.70.3934

食道癌EGFR基因拷贝数崎变与应用易瑞沙的关联

目地易瑞沙是外皮细胞生长因子蛋白激酶(EGFR)酪氨酸激酶缓聚剂,“食道癌易瑞沙实验”说明,在晚中后期食道癌有机化学治疗法后病症发展的病患者中,相对性于安慰剂效应,用易瑞沙可以提升无进度存活時间,在极少数病患者中留意到有迅速长久的减轻。因而,大家推断,根据EGFR通道上的遗传基因崎变很有可能可以鉴别出易瑞沙获利的病患者。方式大家对“食管癌易瑞沙实验”开展了一项事先制定的盲法分子结构剖析,依照EGFR拷贝数增益值(CNG)、EGFR、KRAS、BRAF及其PIK3CA基因突变情况,较为易瑞沙与安慰剂效应的治疗效果。选用事先制定的规范,用原点莹光混种杂交(FISH)技术性查验EGFR拷贝数增益值(CNG),将性染色体多体或增加判断为EGFR FISH呈阳性。結果349名病患者有微生物标识物数据信息,在EGFR FISH阳性肿瘤(20.2%)中,易瑞沙与对照组对比,总存活時间提升(过世风险比[HR],0.59;95%CI,0.35-1.00;P=0.05)。在EGFR FISH呈阴性恶性肿瘤中,易瑞沙与安慰剂效应相较为,总存活時间无差别(过世风险比HR,0.90;95%CI,0.69-1.18;P=0.46)。EGFR增加病患者(7.2%)用易瑞沙获利较大 (过世风险比HR,0.21;95%CI,0.07-0.64;P=0.006)。针对EGFR、KRAS、BRAF及其PIK3CA基因突变的病患者,或是针对其余一切基因突变较为无转变的病患者,用易瑞沙的总存活時间与用安慰剂效应无差别。结果根据FISH技术性点评EGFR拷贝数增益值(CNG)可以鉴别出应用易瑞沙很有可能获利的食道癌病患者,开展二线医治。本探讨结果显示,在EGFR FISH呈阳性、尤其是EGFR增加的食道癌的不一样类型中,理应开展抗EGFR医治的创新性临床试验科学研究。

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer

DOI: http://dx.doi.org/10.1200/JCO.2016.70.3934PurposeThe Cancer Esophagus Gefitinib trial demonstrated improved progression-free survival with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib relative to placebo in patients with advanced esophageal cancer who had disease progression after chemotherapy. Rapid and durable responses were observed in a minority of patients. We hypothesized that genetic aberration of the EGFR pathway would identify patients benefitting from gefitinib.MethodsA prespecified, blinded molecular analysis of Cancer Esophagus Gefitinib trial tumors was conducted to compare efficacy of gefitinib with that of placebo according to EGFR copy number gain (CNG) and EGFR, KRAS, BRAF, and PIK3CA mutation status. EGFR CNG was determined by fluorescent in situ hybridization (FISH) using prespecified criteria and EGFR FISH-positive status was defined as high polysomy or amplification.ResultsBiomarker data were available for 340 patients. In EGFR FISH-positive tumors (20.2%), overall survival was improved with gefitinib compared with placebo (hazard ratio [HR英国《临床肿瘤杂志》:这类种类的食道癌用易瑞沙实际效果最好] for death, 0.59; 95% CI, 0.35 to 1.00; P = .05). In EGFR FISH-negative tumors, there was no difference in overall survival with gefitinib compared with placebo (HR for death, 0.90; 95% CI, 0.69 to 1.18; P = .46). Patients with EGFR amplification (7.2%) gained greatest benefit from gefitinib (HR for death, 0.21; 95% CI, 0.07 to 0.64; P = .006). There was no difference in overall survival for gefitinib versus placebo for patients with EGFR, KRAS, BRAF, and PIK3CA mutations, or for any mutation versus none.ConclusionEGFR CNG assessed by FISH appears to identify a subgroup of patients with esophageal cancer who may benefit from gefitinib as a second-line treatment. Results of this study suggest that anti-EGFR therapies should be investigated in prospective clinical trials in different settings in EGFR FISH-positive and, in particular, EGFR-amplified esophageal cancer.《壹篇》 南南和晨晨《壹篇》系关键朝向医护人员的服务性【微信号码:yaodaoyaofang】,不因盈利为目地,不开展一切有偿服务资询和服务项目,不销售一切商品,与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络,都不意味着一切官方网学好发音。文章照片均来源于互联网,不做商业行为,若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信:india2080】、称赞和分享——【手机微信:india2080】是一种心态和适用。
药道网:易瑞沙是靶向药物吗。

weinxin
我的微信
微信扫一扫
南亚先生
  • 本文由 发表于 2021年11月11日09:46:48
  • 转载请务必保留本文链接:https://www.buy180.com/news/linchuangyaowu/57067.html